The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IWWM-11 2022 | An insight into molecular clusters and tumor-immune drivers in WM
Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, discusses the clinical variation of molecular clusters and tumor-immune drivers in Waldenström’s macroglobulinemia (WM), highlighting findings from a study which used a multi-omics approach to characterize patients. Prof. Ansell explains how these clusters may play a role in disease progression and further comments on the role of the tumor immune microenvironment in WM. This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research funding from Seattle Genetics, BMS, Affimed, Regeneron, Takeda, AstraZeneca, Pfizer, ADC Therapeutics to my institution for clinical trials.
